| scholarly article | Q13442814 |
| P50 | author | Giovanni Delogu | Q39823012 |
| Gabriele Di Sante | Q54677042 | ||
| Riccardo Manganelli | Q56451880 | ||
| Alessandro Cascioferro | Q56852415 | ||
| Michela Sali | Q56863282 | ||
| Stefano Rocca | Q61804054 | ||
| Giorgio Palù | Q67154939 | ||
| P2093 | author name string | Matteo Morandi | |
| Giovanni Fadda | |||
| Chiara Nicolò | |||
| Annabella Procoli | |||
| Francesco Ria | |||
| Valentina Donà | |||
| Antonella Zumbo | |||
| P2860 | cites work | XDR-TB in South Africa: no time for denial or complacency | Q21563425 |
| A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis | Q24554444 | ||
| A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers | Q24657992 | ||
| Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model | Q24675231 | ||
| Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure | Q28486966 | ||
| The quest for a new vaccine against tuberculosis. | Q30380621 | ||
| Development of new tuberculosis vaccines: a global perspective on regulatory issues | Q33293376 | ||
| Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung | Q33389187 | ||
| Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose | Q33468422 | ||
| Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin | Q33919973 | ||
| Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences | Q34001848 | ||
| DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. | Q34004529 | ||
| Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis | Q34005845 | ||
| Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. | Q34007101 | ||
| DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis | Q34116255 | ||
| Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature | Q34349749 | ||
| Virulence, immunogenicity, and protective efficacy of two recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing the antigen ESAT-6 from Mycobacterium tuberculosis | Q34853792 | ||
| Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis | Q35106031 | ||
| Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines | Q36010543 | ||
| What's good for the host is good for the bug. | Q36057658 | ||
| Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes | Q36069312 | ||
| The success and failure of BCG - implications for a novel tuberculosis vaccine | Q36191944 | ||
| Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine | Q36361980 | ||
| Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. | Q36364180 | ||
| Alteration at a single amino acid residue in the T cell receptor alpha chain complementarity determining region 2 changes the differentiation of naive CD4 T cells in response to antigen from T helper cell type 1 (Th1) to Th2. | Q36368633 | ||
| Collagen-specific T-cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis | Q37129563 | ||
| Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection | Q37273289 | ||
| Tuberculosis vaccine research: the impact of immunology | Q37511307 | ||
| Recombinant Mycobacterium bovis BCG. | Q37589871 | ||
| Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. | Q39208280 | ||
| Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis | Q39842246 | ||
| PE_PGRS proteins are differentially expressed by Mycobacterium tuberculosis in host tissues | Q40263062 | ||
| Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy | Q40662782 | ||
| Mouse T-cell receptor variable gene segment families | Q40940168 | ||
| PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall | Q42637560 | ||
| Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy | Q42655798 | ||
| Is selection for TCR affinity a factor in cytokine polarization? | Q43697227 | ||
| Construction and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M protein of porcine reproductive respiratory syndrome virus. | Q44593806 | ||
| Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis | Q44681127 | ||
| Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination | Q46609031 | ||
| Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital | Q46826206 | ||
| Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. | Q46939320 | ||
| Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein | Q47371281 | ||
| Selection of similar naive T cell repertoires but induction of distinct T cell responses by native and modified antigen | Q47991984 | ||
| More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4. | Q51770507 | ||
| Administration of PLP139-151 Primes T Cells Distinct from Those Spontaneously Responsive In Vitro to This Antigen | Q57235894 | ||
| Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis | Q57984777 | ||
| Immune responses induced by recombinant BCG strains according to level of production of a foreign antigen: MalE | Q61053106 | ||
| Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs | Q64133897 | ||
| The interplay between the duration of TCR and cytokine signaling determines T cell polarization | Q73281837 | ||
| Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion | Q73552827 | ||
| Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine | Q79319115 | ||
| Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice | Q79370179 | ||
| Mycobacterium tuberculosis in the adjuvant modulates the balance of Th immune response to self-antigen of the CNS without influencing a "core" repertoire of specific T cells | Q82271491 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| Mycobacterium bovis | Q133447 | ||
| P304 | page(s) | 5202-5213 | |
| P577 | publication date | 2010-10-04 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice | |
| P478 | volume | 78 |
| Q38360635 | A PE_PGRS33 protein of Mycobacterium tuberculosis: an ideal target for future tuberculosis vaccine design |
| Q33784457 | Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system |
| Q31028998 | Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination |
| Q90573361 | Construction and Characterization of the Mycobacterium tuberculosis sigE fadD26 Unmarked Double Mutant as a Vaccine Candidate |
| Q44391246 | Divergence of immunologic and protective responses of different BCG strains in a murine model |
| Q34081754 | Functional dissection of the PE domain responsible for translocation of PE_PGRS33 across the mycobacterial cell wall |
| Q60920166 | Homologous prime boosting based on intranasal delivery of non-pathogenic invasive Escherichia coli expressing MPT64, decreases Mycobacterium tuberculosis dissemination |
| Q34497692 | Impact of protein domains on PE_PGRS30 polar localization in Mycobacteria |
| Q60920160 | Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface |
| Q35645947 | Monosodium Urate Crystals Promote Innate Anti-Mycobacterial Immunity and Improve BCG Efficacy as a Vaccine against Tuberculosis |
| Q38539493 | Mycobacterium tuberculosis virulence: insights and impact on vaccine development |
| Q49829375 | Next-Generation Vaccines Based on Bacille Calmette-Guérin. |
| Q93057164 | Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry |
| Q47425349 | PE and PPE Genes: A Tale of Conservation and Diversity |
| Q58453157 | PE_PGRS30 is required for the full virulence of Mycobacterium tuberculosis |
| Q35957768 | PE_PGRS33 Contributes to Mycobacterium tuberculosis Entry in Macrophages through Interaction with TLR2 |
| Q59806879 | Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens |
| Q38207991 | Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory |
| Q38363789 | Release of mycobacterial antigens |
| Q39203406 | The Enigmatic PE/PPE Multigene Family of Mycobacteria and Tuberculosis Vaccination |
| Q34613099 | The PPE domain of PPE17 is responsible for its surface localization and can be used to express heterologous proteins on the mycobacterial surface |
| Q47367907 | Transglutaminase type 2 plays a key role in the pathogenesis of Mycobacterium tuberculosis infection. |
| Q92857461 | Tuberculosis vaccine candidates based on mycobacterial cell envelope components |
| Q34298426 | rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B. |
Search more.